Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Smith & Nephew Snats ADR (SNN)

Smith & Nephew Snats ADR (SNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,060,856
  • Shares Outstanding, K 437,188
  • Annual Sales, $ 5,549 M
  • Annual Income, $ 263,000 K
  • EBIT $ 0 M
  • EBITDA $ 1,108 M
  • 60-Month Beta 0.84
  • Price/Sales 2.02
  • Price/Cash Flow 7.99
  • Price/Book 2.16

Options Overview Details

View History
  • Implied Volatility 55.88% ( -2.40%)
  • Historical Volatility 45.86%
  • IV Percentile 88%
  • IV Rank 64.63%
  • IV High 79.73% on 08/22/24
  • IV Low 12.29% on 10/02/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 382
  • Open Int (30-Day) 323

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.85 +6.00%
on 11/06/24
25.84 -2.17%
on 12/02/24
-0.28 (-1.10%)
since 11/05/24
3-Month
23.85 +6.00%
on 11/06/24
31.72 -20.30%
on 09/09/24
-5.95 (-19.05%)
since 09/05/24
52-Week
23.65 +6.89%
on 04/16/24
31.72 -20.30%
on 09/09/24
-0.44 (-1.71%)
since 12/05/23

Most Recent Stories

More News
SNN Stock May Gain Following the Co-Marketing Deal With JointVue

Smith & Nephew SNATS SNN recently announced the signing of a co-marketing agreement with JointVue for its patented OrthoSonic 3D Surgery Planning Technology, which is the only ultrasound device currently...

SNN : 25.28 (-0.08%)
BSX : 90.53 (-0.34%)
BAX : 31.90 (-3.39%)
DVA : 161.37 (-1.23%)
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System

Smith & Nephew SNATS SNN recently launched its LEGION Hinged Knee System, which incorporates its proprietary OXINIUM Technology. The launch marks a significant advancement in the field of knee revisions,...

ZBH : 109.16 (-1.32%)
SNN : 25.28 (-0.08%)
SYK : 382.45 (-1.88%)
MDT : 84.14 (-1.38%)
Smith+Nephew opens new state-of-the-art surgical innovation and training centre in the heart of Munich

/PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company specialising in orthopaedics, advanced wound management and sports...

SNN : 25.28 (-0.08%)
Smith+Nephew opens new state-of-the-art surgical innovation and training centre in the heart of Munich

/CNW/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company specialising in orthopaedics, advanced wound management and sports medicine,...

SNN : 25.28 (-0.08%)
Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand

Surgery centers and medtech firms see a surge in demand as joint replacements and other elective surgeries are rescheduled, causing challenges for insurers.

BSX : 90.53 (-0.34%)
CNC : 57.95 (-3.05%)
HUM : 283.06 (-1.74%)
ISRG : 547.65 (-0.42%)
THC : 138.90 (-1.84%)
UNH : 578.97 (-5.21%)
SGRY : 21.46 (-4.71%)
ZBH : 109.16 (-1.32%)
ELV : 392.98 (-1.38%)
HCA : 320.05 (-1.25%)
SNN : 25.28 (-0.08%)
Smith+Nephew announces 510(k) clearance of its AETOSâ„¢ Shoulder System for anatomic and reverse shoulder replacement

/PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States...

SNN : 25.28 (-0.08%)
Smith+Nephew introduces first of its kind handheld digital tensioning device for robotically-enabled total knee arthroplasty

/PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today introduced its new CORIâ„¢ Digital Tensioner - a purpose built...

SNN : 25.28 (-0.08%)
3 Healthcare Dividend Payers With Big Price Growth

Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers. 

SNY : 48.51 (+1.04%)
AZN : 67.53 (+1.12%)
SNN : 25.28 (-0.08%)
Stocks Move Higher Before the Open as Market Sentiment Improves, U.S. Inflation Data on Tap

June S&P 500 futures (ESM23) are up +0.21%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.28% this morning as market participants continued to assess the path of Federal Reserve monetary policy...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
CAT : 394.98 (-1.13%)
WDC : 72.11 (-0.32%)
MU : 100.87 (-2.26%)
AAPL : 243.04 (+0.01%)
JPM : 245.48 (+0.85%)
WFC : 73.66 (+0.82%)
C : 72.23 (+1.02%)
CINE.LN : 0.381 (unch)
TLRY : 1.3000 (+1.56%)
HEXO : 0.7100 (+2.45%)
New evidence demonstrates Smith+Nephew's COBLATIONâ„¢ Technology can accelerate patient recovery with fewer complications compared with total tonsillectomy techniques

/PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces results from new scientific research that shows its...

SNN : 25.28 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative...

See More

Key Turning Points

3rd Resistance Point 25.66
2nd Resistance Point 25.57
1st Resistance Point 25.43
Last Price 25.28
1st Support Level 25.20
2nd Support Level 25.11
3rd Support Level 24.97

See More

52-Week High 31.72
Fibonacci 61.8% 28.64
Fibonacci 50% 27.68
Fibonacci 38.2% 26.73
Last Price 25.28
52-Week Low 23.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar